Alec C Kimmelman

Title: Alec C Kimmelman: Innovator in Cancer Treatment

Introduction

Alec C Kimmelman is a prominent inventor based in Weston, MA (US), known for his significant contributions to cancer research and treatment. With a total of 4 patents, Kimmelman has focused on innovative methods to combat oncogenic Kras-associated cancers and improve autophagic targeting of ferritin.

Latest Patents

Kimmelman's latest patents include groundbreaking work on targeting the glutamine to pyruvate pathway for the treatment of oncogenic Kras-associated cancer. This patent provides methods and kits for GPP-targeting, specifically aimed at treating oncogenic Kras-associated cancers, along with methods for determining the efficacy of these treatments. Another notable patent involves compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin. This patent describes methods for modulating the autophagic targeting of ferritin in a cell by adjusting the level and/or activity of nuclear receptor coactivator 4 (NCOA4), along with related treatment methods.

Career Highlights

Throughout his career, Kimmelman has worked with esteemed institutions such as Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. His work has significantly advanced the understanding and treatment of cancer, particularly in relation to metabolic pathways and autophagy.

Collaborations

Kimmelman has collaborated with notable figures in the field, including Lewis C Cantley and Costas A Lyssiotis. These collaborations have further enriched his research and contributed to the development of innovative cancer therapies.

Conclusion

Alec C Kimmelman stands out as a key innovator in the field of cancer treatment, with a focus on metabolic pathways and autophagy. His patents and collaborations reflect his commitment to advancing cancer research and improving patient outcomes.